Close Menu

Scientists at Roche have used computational methods to screen for small molecule kinase inhibitors (SMKIs) that bind to more than one kinase and cause damage to chromosomes. Using a competitive binding assay, they tested the binding affinity of 113 SMKIs against a representative subset of all 290 kinases. They were able to identify kinases that correlate with chromosome damage, "providing a basis for rational drug design away from genotoxicity," they say.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.